07-Jul-2008
Story Timeline: 97 days
WASHINGTON (Reuters) - U.S. Food and Drug Administration officials will seek a strong "black box" warning for epilepsy drugs cautioning about the risk of suicidal thoughts and behavior, an agency spokeswoman told Reuters on Monday. "We are going to ask for a boxed warning on these drugs," said FDA spokeswoman Sandy Walsh. The news comes ahead of an FDA advisory panel meeting on Thursday to discuss the drugs' risks. The FDA plans to seek comment from its outside advisers on the proposed warning, Walsh said. GlaxoSmithKline Plc's Lamictal and Pfizer Inc's Lyrica are among the top-selling epilepsy drugs. Others include Johnson & Johnson's Topamax and Abbott Laboratories Inc's Depakote. (Reporting by Susan Heavey; editing by John Wallace) Next Article: FACTBOX-Details of Fed, SEC investment bank...
[read full story]